Buparlisib demonstrated important anti-proliferative activity in either mutant or wild-type KRAS CCA cells [112], while the inhibitor PI-103 affect cell proliferation in a xenograft CCA mouse model [113]. The gene discussed is KRAS; the disease is cholangiocarcinoma.